Review Article

Pharmacologic Agents Used to Reverse the Anticoagulant Effect of Common Anticoagulants

Authors: James M. Wooten, PharmD, Steven T. Baldwin, MD

Abstract

Numerous oral and parenteral anticoagulant drugs are now available for clinical use. Understanding the precise pharmacologic properties of each anticoagulant is imperative for those practitioners who prescribe these drugs, including knowing the current recommendations for reversing the anticoagulant effect of each anticoagulant. This review provides a brief description of the various anticoagulants used today and also discusses the pharmacologic properties of those drugs used to reverse the anticoagulant action of specific anticoagulants.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Mujer MTP, Rai MP, Atti V, et al. An update on the reversal of non-vitamin K antagonist oral anticoagulants. Adv Hematol 2020;2020:7636104.
 
2. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020;76:594–622.
 
3. Yee J, Kaide CG. Emergency reversal of anticoagulation. West J Emerg Med 2019;20:770–783.
 
4. Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals (Basel) 2016;9:38.
 
5. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001;21:1094–1096.
 
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S–203S.
 
7. Morris T. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med 2003;24:39–47.
 
8. Holzmacher JL, Sarani B. Indications and methods of anticoagulation reversal. Surg Clin N Am 2017;97:1291–1305.
 
9. Boer C, Meesters MI, Veerhoek D, et al. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth 2018;120: 914–927.
 
10. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care 2015;24:6–46.
 
11. Nutescu EA, Burnett A, Fanikos J, et al. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41:15–31.
 
12. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20:37–52.
 
13. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011;72: 581–592.
 
14. Winkler AM, Tormey CA. Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients. The Education Committee of the Academy of Clinical Laboratory Physicians and Scientists (ACLPS). Am J Clin Pathol 2013;140:610–622.
 
15. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006;62:509–511.
 
16. Hirsh J, Fuster V, Ansell J, et al. American Heart Association, American College of Cardiology Foundation, American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692–1711.
 
17. Regal RE, Tsui V. Optimal understanding of warfarin: beyond the nomogram. https://www.semanticscholar.org/paper/Optimal-understanding-of-warfarin% 3A-Beyond-the-Regal-Tsui/ffd2e38167c67da2e61c43940c7c518667940780. Published October 1, 2004. Accessed January 12, 2022.
 
18. Schein JR, White CM, Nelson WW, et al. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016;14:14.
 
19. Thigpen JL, Limdi NA. Reversal of oral anticoagulation. Pharmacotherapy 2013;33:1199–1213.
 
20. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. Ann Pharmacother 2012;46:1617–1626.
 
21. Britt RB, Brown JN. Characterizing the severe reactions of parenteral vitamin K1. Clin Appl Thromb Hemost 2018;24:5–12.
 
22. Cada DJ, Levien TL, Baker DE. Prothrombin complex concentrate. Hosp Pharm 2013;48:951–957.
 
23. Chacko B, Peter JV, Subramani K. Reversal of anticoagulants in critical care. Indian J Crit Care Med 2019;23(Suppl 3):S221–S225.
 
24. Only AJ, DeChristopher DJ, Iqal O, et al. Restoration of normal prothrombin time/international normalized ratio with fresh frozen plasma in hypocoagulable patients. Clin Appl Thromb Hemost 2016;22:85–91.
 
25. Thakur J, Chaudhary A, Tomar B, et al. Review on chemistry and pharmacology of dabigatran a potent anticoagulant. World J Pharm Pharmaceut Sci 2019;9: 612–628.
 
26. Roca B, Roca M. The new oral anticoagulants: reasonable alternatives to warfarin. Clev Clin J Med 2015;82:847–854.
 
27. Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios—Is there a general consensus? Am J Emerg Med 2020;38:1890–1903.
 
28. Praxbind (idarucizumab) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2020.
 
29. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants. Arterioscler Thromb Vasc Biol 2015;35:1056–1065.
 
30. Krishna R, Kumar BS, Krishnan S, et al. A review of novel anticoagulants. Int J Pharm Clin Res 2017;9:96–99.
 
31. Salem JE, Sabouret P, Funck-Brentano C, et al. Pharmacology and mechanisms of action of the new oral anticoagulants. Fundam Clin Pharmacol 2015;29: 10–20.
 
32. Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020;9:e017559.
 
33. Jain N, Reilly RF. Clinical pharmacology of oral anticoagulants in patients with kidney disease. Clin J Am Soc Nephrol 2019;14:278–287.
 
34. Andexxa [package insert]. South San Francisco, CA: Portola Pharmaceuticals; 2020.
 
35. Momin JH, Hughes GH. Andexanet alfa (Andexxa®) for the reversal of direct oral anticoagulants. P T 2019;44:530–533.
 
36. Carpenter E, Singh D, Dietrich E, et al. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf 2019;10:1–12.
 
37. Ansel J, Laulicht BE, Bakhru SH, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood 2021;137:115–125.
 
38. Hornor MA, Duane TM, Ehlers AP, et al. American College of Surgeons’ Guidelines for the Perioperative Management of Antithrombotic Medication. J Am Coll Surg 2018;227:521–536.e1.